壽康集團(00575.HK)年度淨虧損約1260萬美元
格隆匯3月29日丨壽康集團(00575.HK)公佈年度業績,截至2021年12月31日止12個月,公司股東應占虧損約1260萬美元,主要由於:(i)無形資產攤銷費用(非現金項目)約2376萬美元;(ii)集團的運營和研發開支約為835萬美元;同時被以下部分抵銷:(iii)公司股本投資組合內的透過損益賬按公允價值處理之金融資產之已變現和未變現按市值計價收益分別約為485萬美元和874萬美元;(iv)里程碑收益320萬美元,以及(v)公司衍生金融工具的未變現收益約120萬美元。
集團收到江蘇萬邦醫藥支付關於於2021年2月5日獲得中國藥品審評中心的臨牀試驗批准的288萬美元(扣除中國預扣税10%後)。自年度結束起,江蘇萬邦醫藥已展開隨機化臨牀試驗工作,預計於展開後12個月內完成。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.